In this week’s episode, the Medical Services Advisory Committee’s rejection of adding Pompe disease to newborn blood spot screening is condemned. The decision is contemptuous, inhumane, and riddled with fabricated justifications based on made-u...

Patients should never accept a decision-making framework that requires them to sacrifice themselves for a mythical collective good, which is just the government getting the best deal for itself. More evidence of why we need to know what discuss...

The minister focused on NDIS reform at this week's National Press Club address, suggesting that it is taking up a lot of his time. Implementing the HTA Review will be one side of a two-sided coin. While it might frustrate some, it represents a ...

An update on the Government's travel policy! The opportunity of AI, our own journeys, and why it needs to be embraced and not feared, particularly in healthcare. Productivity and the impact of chronic conditions and another example of why it wo...

Government travel policies make us laugh and laugh. Understanding reforms from the government's perspective is critical to understand how they will evolve over time, and an update that raises more questions than it answers.

A special episode focused on the AbbVie-commissioned survey, revealing firm support for increased investment in medicines and the true extent of patients paying the cost of their prescriptions. What does it mean and what is the opportunity?

Another order on pharmaceutical pricing, but what does it mean? What does the Government's productivity roundtable have in common with the HTA Review? Screening programs that aren't, and a co-payment reduction that puts the safety net further o...

A sense of entitlement that needs to be questioned, Australia is on the list of nine countries to be targeted over pharmaceutical pricing, and the hopeless hypocrisy of allowing a group of disreputable regimes to have a say on this country's re...

The opportunity for Australia is to do less deflecting on healthcare affordability and engage in an honest discussion about the genuine challenges confronting many Australians. The debate does not just deflect on affordability.

The ongoing debate regarding the US, the Trump administration's potential tariffs on pharmaceuticals and the PBS is mainly characterised by falsehoods and errors. We discuss our incredible frustration over a debate that is almost entirely disco...

We have more health commissioners, including for genomics, and we both hope for a more meaningful discussion on weight loss therapies, the opportunities, access barriers, and their system-changing impact. Telehealth is here to stay, particularl...

The health department has released its incoming ministerial brief to the reappointed Mark Butler, revealing internal government discussions over the future funding of new PBS listings, and hinting at limiting the implementation of the HTA Revie...

In a country as wealthy as Australia, how is it fair or equitable that some can pay for new treatments, while most are forced to wait, while the government uses a laborious multi-year process to negotiate the best deal for itself? We are forced...

Adding disability to health in an already full ministerial bandwidth and funding challenges. Trade policy and the PBS, and a presentation on the human consequences of our decision-making. Can a targeted diagnostic screening and the strangest pa...

A busy two weeks with an election and the addition of disability and the NDIS to the health portfolio. What does it mean? The credulous reflex response to comparisons between the US and Australian health systems. Why is denying access and out-o...

What is the balance between building national sovereignty in health and protecting patient safety and community confidence in new technologies? Do we need to be careful? An election brings back memories of 'future' funds past.

The health election debate mainly concerned bulk billing. New bureaucracies are rarely the solution to anything, and the challenge of faster funded access to new health technologies, particularly when advisory committees with power appear oppos...

Australia's election is two weeks in, and we're having trouble engaging. How positional power and 'expertism' can be confused and the value of a transparent and open forum.

The industry's 'Faustian bargain' on the 'sanctity' of the PBS, the challenge so many have in being clear about the problem, and why Pathology Australia provides an important lesson. Another wrong political message on newborns, why dentists mig...

US criticism of the PBS is like catnip for some people, they can't resist it, even if it's the same criticism articulated by multiple Australian stakeholders and the health minister. The strange secrecy over the government's review of arrangeme...

A total victory for pharmacy with the prime minister's appearance at their showcase annual event. We discuss the confected outrage over US interest in the PBS, which is hardly new, and why the industry needs to lead this debate because its repu...

Medicines Australia will be appointing a new chair. To what extent does it matter? The participation model means that the industry might be effectively shackled to the 'change' table rather than having a seat at it. The government has worked it...

A review of Senate Estimates, with irritating warnings, too much passivity, and passive-aggressive responses (0.00-4.50). Revelations on how oral contraceptives navigated the funding process and the drivers of that outcome (4.51-14.10). We disa...

A serious discussion about reforming Australia's use of health technology assessment should start with patient rights and the imposition of new obligations on advisory committees and decision-makers. The signs of institutional capture and the d...